Evaluating an Elevated Screening PSA Test

Evaluating an Elevated Screening PSA Test

The percentage of prostate-specific antigen (PSA) circulating free is sometimes used to estimate the likelihood of prostate cancer for men with mildly elevated PSA levels. However, finding reassuring levels of free PSA (>25%) is unusual. New prostate cancer biomarkers are emerging but have not ye...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA : the journal of the American Medical Association 2015-11, Vol.314 (19), p.2073-2074
Hauptverfasser: Barry, Michael J, Hayes, Julia H
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Humans
Male
Medical screening
Mens health
Middle Aged
Probability
Prostate cancer
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - blood
Prostatic Hyperplasia - diagnosis
Prostatic Neoplasms - diagnosis
Sensitivity and Specificity
Watchful Waiting
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The percentage of prostate-specific antigen (PSA) circulating free is sometimes used to estimate the likelihood of prostate cancer for men with mildly elevated PSA levels. However, finding reassuring levels of free PSA (>25%) is unusual. New prostate cancer biomarkers are emerging but have not yet been shown to be associated with lower prostate cancer mortality. Here, Barry and Hayes examine the case of 59-year-old white man who undergo PSA screening for prostate cancer.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.2015.12614